在国内生物医药产业向创新化、多元化升级的浪潮中，长春高新技术产业（集团）股份有限公司（以下 简称"长春高新"）凭借对细分赛道的精准把控，勾勒出生长激素、多元商业化创新产品、新药"出海"授 权"三驾马车"并驾齐驱的全新格局。 今年9月份，长春高新旗下核心子公司长春金赛药业有限责任公司（以下简称"金赛药业"）与丹麦ALK- AbellóA/S公司（以下简称"ALK"）达成变应原特异性免疫治疗（AIT，俗称脱敏治疗）产品合作，将在 中国联合开发并商业化ALK的屋尘螨（HDM）变应原特异性免疫治疗产品，并获得ALK自主开发的3款 产品在中国大陆范围内的独家代理权益。 "脱敏，是我们全力进军免疫与呼吸领域的关键一步，是公司未来重要的业务增长点。未来，金赛药业 力争跻身中国呼吸领域第一梯队。"长春高新总经理，金赛药业创始人、总经理、首席科学家金磊对 《证券日报》记者表示。 在竞争激烈的生物医药领域，如何通过研发创新实现攻势突破、通过多元化与资本运作稳固防线、通过 国际化布局实现护城河延展，是长春高新面临的三道命题。近日，《证券日报》记者走进长春高新，探 寻公司攻与守的博弈之道。 创新为本 筑牢发展基石 创新研发是企业生存 ...

9月26日，长春高新涨5.09%，截至发稿，报128.80元/股，成交7.77亿元，换手率1.53%，总市值525.42 亿元。 资料显示，长春高新技术产业(集团)股份有限公司位于吉林省长春市高新海容广场B座27层(震宇街与东 蔚山路交汇)，成立日期1993年6月10日，上市日期1996年12月18日，公司主营业务涉及生物制药及中成 药的研发、生产和销售,辅以房地产开发、物业管理和服务等业务。主营业务收入构成为：制药业 92.83%，房地产6.81%，服务业0.36%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 从基金十大重仓股角度 责任编辑：小浪快报 中信保诚中证800医药指数(LOF)A（165519）基金经理为黄稚。 截至发稿，黄稚累计任职时间7年66天，现任基金资产总规模30.1亿元，任职期间最佳基金回报 146.63%， 任职期间最差基金回报-20.24%。 数据显示，中信保诚基金旗下1只基金重仓长春高新。中信保诚中证800医药指数(LOF)A（16551 ...

天风证券研报指出，长春高新与ALK合作，有望开启中国脱敏新时代。本次合作产品包括ALK自主开 发的2款变应原特异性免疫治疗产品和1款用于过敏原诊断的皮肤点刺试剂盒。中国拥有全球尘螨过敏患 者最大的患者人群，但中国过敏免疫疗法市场开发不足、缺乏创新产品。目前接受脱敏治疗的患者数量 不足100万，存在大量未满足临床需求。认为此次合作有望与金赛的生长激素产品形成协同，横向拓展 公司产品线。维持"买入"评级。 ...

华鑫证券研报指出，长春高新控股子公司长春金赛药业有限责任公司与丹麦ALK-AbellóA/S公司达成变 应原特异性免疫治疗（AIT）产品合作。此次合作金赛药业将获得ALK自主开发的3款产品在中国大陆 范围内的独家代理权益，其中皮下注射剂型已在中国大陆上市，舌下片剂型正处于Ⅲ期桥接临床研究阶 段。中国也是全球最大尘螨脱敏治疗市场，2023年市场总量超过11亿人民币，3年复合增速12%。金赛 药业与ALK合作期限至2039年，经过长期培育，脱敏领域有望成为金赛药业重要的新增长点。另外， 公司伏欣奇拜单抗为国内首款抗白介素1β（IL-1β）全人源单抗，2025年6月正式获批上市，填补了我国 痛风抗炎领域长效精准靶向治疗的空白。研发投入的增加，子公司金赛药业得以吸引新进人才，并构建 起以ADC为核心的肿瘤新药开发平台。给予"买入"投资评级。 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Investment Rating - The report maintains a "Buy" investment rating for the company [1][9]. Core Insights - The collaboration with ALK-Abelló A/S aims to expand the desensitization treatment market, potentially creating new growth points for the company [5]. - The launch of Fuxin Qibai monoclonal antibody addresses the acute treatment of gout, filling a gap in the long-acting targeted therapy market in China [6]. - The company is increasing its R&D investment, particularly in the oncology sector, with a focus on developing new drugs based on ADC technology [7][8]. - Revenue forecasts for 2025-2027 are projected at 133.25 billion, 136.94 billion, and 137.85 billion yuan respectively, with corresponding EPS of 5.66, 5.88, and 6.00 yuan [9][11]. Summary by Sections Market Performance - The current stock price is 120.5 yuan, with a total market capitalization of 49.2 billion yuan and a total share count of 408 million [1]. Investment Highlights - The partnership with ALK allows the company to exclusively distribute three products in mainland China, enhancing its market share in the desensitization treatment sector [5]. - The pediatric market for allergy treatments is significant, with a prevalence rate of 18.46% among children aged 0-18 in China, indicating a strong potential for growth [5]. - Fuxin Qibai has shown promising clinical results, with a 90% reduction in gout recurrence risk at 12 weeks, suggesting a sales potential exceeding 20 billion yuan [6]. R&D Investment - In the first half of 2025, the company invested 1.335 billion yuan in R&D, a 17.32% increase year-on-year, representing 20.21% of its revenue [7]. - The increase in R&D spending is aimed at attracting new talent and establishing a new drug development platform focused on oncology [8]. Financial Projections - The company anticipates a decline in revenue growth rates, with a forecasted decrease of 7.6% in 2024, followed by a slight recovery in subsequent years [11]. - The projected net profit for 2025 is 2.308 billion yuan, reflecting a 10.6% decrease from the previous year [11].

Investment Rating - The investment rating for Changchun High-tech is "Buy" with a target price not specified [5] Core Views - The collaboration with ALK is expected to open a new era in desensitization treatment in China, focusing on allergen-specific immunotherapy products [1][2] - The partnership includes exclusive rights for three products in mainland China, with a collaboration period until December 31, 2039 [2] - The company is projected to have revenue of 135.96 billion, 141.92 billion, and 151.61 billion CNY for the years 2025, 2026, and 2027 respectively, with net profits of 23.89 billion, 25.45 billion, and 28.09 billion CNY for the same years [3] Summary by Sections Collaboration Details - Changchun High-tech has signed a cooperation agreement with ALK to develop and commercialize allergen-specific immunotherapy products in China [1] - The products include subcutaneous allergen extracts and a skin prick test kit, with Changchun High-tech responsible for sales and promotion in the region [2] Market Potential - China has the largest population of dust mite allergy patients globally, yet the market for allergy immunotherapy is underdeveloped, indicating significant unmet clinical needs [3] Financial Projections - Revenue estimates for 2025-2027 are 135.96 billion, 141.92 billion, and 151.61 billion CNY, with net profits projected at 23.89 billion, 25.45 billion, and 28.09 billion CNY [3] - The company anticipates a decline in revenue and profit due to increased market competition, leading to a downward adjustment in previous forecasts [3] Financial Metrics - The company’s financial metrics include an expected revenue growth rate of 0.97% in 2025, followed by 4.38% and 6.83% in 2026 and 2027 respectively [4] - The projected earnings per share (EPS) for 2025 is 5.86 CNY, with a price-to-earnings (P/E) ratio of 20.58 [4]

Group 1 - The core viewpoint of the news is that Changchun High-tech has shown a significant stock performance with a year-to-date increase of 24.97%, despite a recent decline of 2.27% over the last five trading days [1] - As of September 24, the stock price reached 121.07 yuan per share, with a total market capitalization of 49.389 billion yuan [1] - The company has seen a net inflow of main funds amounting to 18.2718 million yuan, with large orders contributing significantly to the trading volume [1] Group 2 - Changchun High-tech's main business revenue composition is 92.83% from pharmaceuticals, 6.81% from real estate, and 0.36% from services [1] - As of June 30, the company reported a revenue of 6.603 billion yuan for the first half of 2025, reflecting a year-on-year decrease of 0.54%, while the net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [2] - The company has distributed a total of 4.791 billion yuan in dividends since its A-share listing, with 3.259 billion yuan distributed in the last three years [3] Group 3 - As of June 30, 2025, the number of shareholders decreased by 12.78% to 109,100, while the average circulating shares per person increased by 14.66% to 3,662 shares [2] - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the third-largest shareholder, holding 8.4381 million shares [3] - The company is categorized under the pharmaceutical and biological industry, specifically in the bioproducts sector, and is associated with various investment concepts such as Northeast revitalization and high dividend stocks [2]

9月24日午后，制药板块继续上攻，全市场唯一药ETF（562050）冲高逾2%。 成份股方面，创新药概念领涨，信立泰和甘李药业双双涨停封板！权重股恒瑞医药、百济神州等均飘 红。中药股亦表现不俗，太极集团、东阿阿胶、达仁堂集体涨超2%。 | 分时 多日 1分 5分 · | | | | F9 盘前盘后 露加 九井 画线 工具 @ (2) > | | | | | | | GETF 1 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1,127 | | | 562050[药ETF] 14:06 价 1.127 温康 0.024(2.18%) 均价 1.117 成交盘 .. | | | 1 2.18% | | 1.127 | +0.024 +2.18% | | EGONED 7 | | | 1,119 | | | WAND W | | | 1,45% | | SSE CNY 14:06:07 交易中 | | | | 1 . 4 | | | | | | | | | 净值出现 | | 华富中证制药ET ...

Market Overview - On September 22, the biopharmaceutical sector experienced a slight decline of 0.15%, with Kanglaosheng leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aipumai (688293) with a closing price of 58.70, up 9.90% on a trading volume of 47,100 shares and a turnover of 267 million yuan [1] - Baipusais (301080) closed at 61.75, up 5.05% with a trading volume of 38,300 shares and a turnover of 231 million yuan [1] - Muli Pharmaceutical (603087) closed at 73.60, up 3.76% with a trading volume of 182,000 shares and a turnover of 134.2 million yuan [1] - Conversely, the following stocks saw significant declines: - Kanglaosheng (833575) closed at 14.71, down 6.90% with a trading volume of 90,400 shares and a turnover of 137 million yuan [2] - Kexing Pharmaceutical (688136) closed at 40.54, down 3.20% with a trading volume of 47,600 shares and a turnover of 194 million yuan [2] - Changchun High-tech (000661) closed at 122.10, down 2.49% with a trading volume of 102,800 shares and a turnover of 1.265 billion yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 473 million yuan from institutional investors, while retail investors contributed a net inflow of 418 million yuan [2] - The following stocks had notable capital flows: - Ganli Pharmaceutical (603087) had a net inflow of 58.16 million yuan from institutional investors [3] - Rongchang Biotechnology (688331) saw a net inflow of 43.73 million yuan from institutional investors [3] - ZhiXiangJinTai (688443) had a net inflow of 6.53 million yuan from retail investors [3]